Evidence map›Paper›PMID 24322785›Full record

SynthesisThe pharmacogenomics journal2014

HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis.

E Genin, D-P Chen, S-I Hung, P Sekula, M Schumacher, P-Y Chang, S-H Tsai, T-L Wu, T Bellón, R Tamouza and 8 more

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in The pharmacogenomics journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 6 pooled it
18.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 6 syntheses or guidelines pooled it, 246 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Severe cutaneous adverse reactions.Nature reviews. Disease primers · 2024
    Review

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 4 countries.

E GeninInserm U946, Saint Louis Hospital, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.
D-P Chen1] Department of Laboratory Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan [2] Department of Medical Biotechnology and Laboratory Science, Chang Gung University College of Medicine, Taoyuan, Taiwan.
S-I HungInstitute of Pharmacology, School of Medicine, Infection and Immunity Research Center, National Yang-Ming University, Taipei, Taiwan.
P SekulaInstitute of Medical Biometry and Medical Informatics, Freiburg University-Medical Center, Freiburg, Germany.
M SchumacherInstitute of Medical Biometry and Medical Informatics, Freiburg University-Medical Center, Freiburg, Germany.
P-Y Chang1] Department of Laboratory Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan [2] Department of Medical Biotechnology and Laboratory Science, Chang Gung University College of Medicine, Taoyuan, Taiwan.
S-H Tsai1] Department of Laboratory Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan [2] Department of Medical Biotechnology and Laboratory Science, Chang Gung University College of Medicine, Taoyuan, Taiwan.
T-L Wu1] Department of Laboratory Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan [2] Department of Medical Biotechnology and Laboratory Science, Chang Gung University College of Medicine, Taoyuan, Taiwan.
T BellónResearch Unit, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
R Tamouza1] Jean Dausset Laboratory, Saint Louis Hospital, Paris, France [2] Inserm UMRS 940, Saint Louis Hospital, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.
C Fortier1] Jean Dausset Laboratory, Saint Louis Hospital, Paris, France [2] Inserm UMRS 940, Saint Louis Hospital, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.
A Toubert1] Jean Dausset Laboratory, Saint Louis Hospital, Paris, France [2] Inserm UMRS 940, Saint Louis Hospital, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.
D Charron1] Jean Dausset Laboratory, Saint Louis Hospital, Paris, France [2] Inserm UMRS 940, Saint Louis Hospital, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.
A HovnanianInserm UMRS 940, Saint Louis Hospital, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.
P WolkensteinInserm UMRS 940, Saint Louis Hospital, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.
W-H ChungDepartment of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospitals, Keelung, Linko, Chang Gung University College of Medicine, Taipei, Taiwan.
M MockenhauptDokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Freiburg University-Medical Center, Freiburg, Germany.
J-C RoujeauService Dermatologie, Hôpital Henri-Mondor, Université Paris-Est, Créteil, France.
Hôpital Saint-Louis · FRChang Gung University · TWDélégation Paris 7 · FRUniversity Medical Center Freiburg · DEChang Gung Memorial Hospital · TWHospital Universitario La Paz · ESNational Yang Ming Chiao Tung University · TWUniversité Paris-Est Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HLA-A*31:01 was reported to be associated with carbamazepine (CBZ)-induced severe cutaneous adverse reactions (SCAR), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We conducted an international study using consensus diagnosis criteria to enroll a total of 93 patients with CBZ-SCAR from Europe or Asia. We found that HLA-A*31:01 showed a significant association with CBZ-DRESS in Europeans (P<0.001; odds ratio (OR) (95% confidence interval (CI))=57.6 (11.0-340)), and the strong association was also found in Chinese (P<0.001; OR (95% CI)=23.0 (4.2-125)). However, HLA-A*31:01 had no association with CBZ-SJS/TEN in neither Chinese nor Europeans. By comparison, HLA-B*15:02 showed a strong association with CBZ-SJS/TEN in Chinese (P<0.001, OR (95% CI)=58.1 (17.6-192)). A meta-analysis of this and other published studies confirmed that in all populations, HLA-A*31:01 had an extremely strong association with CBZ-DRESS (P<0.001, a pooled OR (95% CI)=13.2 (8.4-20.8)), but a much weaker association with CBZ-SJS/TEN (P=0.01, OR (95% CI)=3.94 (1.4-11.5)). Our data revealed that HLA-A*31:01 is a specific predictor for CBZ-DRESS but not for CBZ-SJS/TEN. More studies are needed to investigate the genetic determinant of CBZ-SJS/TEN in Europeans. Considering the potential clinical utility, the cost-effectiveness of the combined HLA-A*31:01 and HLA-B*15:02 genetic test to prevent CBZ-SCAR in Chinese needs further investigation.

Indexed as

CarbamazepineCohort StudiesHLA-A AntigensHumansSkinCarbamazepineHLA-A Antigens

Identifiers

PMID24322785
OpenAlexW2104951811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.